See hotcopper. Company now has 33K Eagle Ford net acres as previously reported (14K McMullen and 19K Dimmit). Managed 22M EBITDAX despite the downturn in oil price and projects funding the rest of 2015 capex through operating cashflow. New borrowing base goes into effect during Q2.
No mention of Ph1 efficacy because the trial was in healthy volunteers only
80% improvement for Anavex PLUS over donepezil alone in preclinical study may not be incredible, but it is promising. Anavex 2-73 is not the home run (that's 3-71), but it doesn't need to be. If it just enhances the effect of donepezil that will trigger a partnership that will put many multiples on the pre-Ph2 MC and speed the progress of 3-71.
My favorite Chaucer line, cool. Gotta read the whole Temple of Mars passage to get the full effect.
Phase 1 was in healthy volunteers, so that's why no efficacy data. Human data is not the only basis for optimism, just the best. Preclinical studies still give plenty of legit reason for optimism, especially the synergy with donepezil, though obviously caution is in order and nothing is guaranteed.
Most of those 245 ALZ drugs have targeted AB plaques. 2-73 targets Sigma-1 Receptor. I think that renders the previous ALZ trials much less relevant than most believe.
Agreed, initial data "by Q3" and final data in September. I think once enrollment is complete we will get a preliminary look at primary outcomes for earliest enrollees in the trial.
When I think about it I have to sit down. Every day I argue with myself whether or not to sell any shares in the run-up to ph2 data release. Hopefully the company will just announce positive interim data some random day during the next couple months and take the decision out of my hands. Then I can just hold until Anavex = Pfizer.
still preclinical, have to do manufacturing and toxicology studies before entering phase I. No idea how long that will take, but I'll venture a wild guess at a 2016 initiation of phase I trial.
Exactly. Negative data would cause a big move south, but it is hardly this company's only shot on goal, and I believe 3-71 is an even greater potential blockbuster than 2-73.
If the warrants had already been struck, the market cap right now would be $62M, still dirt cheap. Even fully diluted this is a ridiculous bargain.
I bought my little portion at .15, but definitely not "all this"
As for me, it looked like panic selling and I'm not panicky, so I bought. I like the technology, only spent what I can afford to lose, and will see what happens. If the company stays in business, I think the buy will end up very well. The initial results are promising.
3-71 definitely sounds like the potential blockbuster, with 2-73 (or rather 2-73 plus Aricept) a very worthy set-up. I expect a nice partnership on 2-73 will allow AVXL to keep 3-71 to itself.
Excellent post, thanks! Rare to find anything of substance on this board. The letter is a great reminder both of why I invested in the first place and the great progress made by the company since that time.
And now up to almost 39K acres in the Eagle Ford as of the end of 1Q 2015. So Sundance added about 12K net acres the last three months. That is where the company is really going to make hay with this downturn -- buying distressed leases out from under its weaker neighbors.
Yup, all the price appreciation was before the fact. I was willing to take a little profit at .26 (still keeping my core holding), but it didn't quite get there. That's all right, though--there will be plenty of price appreciation to come. Just a question of when...
No potential buyer cares about Entek's investor relations or how the company operates. Potential buyers care whether or not they can make money off Entek's acreage. I'm pretty sure multi-billionaire Terry Pegula did not care how often Entek's stock trades or think its acreage was too small when he bought into the Battle Mountain AMI. As for low o&g prices, Entek is far from alone in dealing with those and unlike many others, Entek has cash and no debt and will be fine waiting until prices become economic again.